ad

SELLAS Life Sciences Stock Soars 166% After Phase 3 REGAL Leukemia Vaccine Trial Meets Its Survival Goal, With a Further 5% Gain Reported on 18 November

SLS about +166% to $19.84 on 17 Nov from $7.47. REGAL hazard ratio 0.59, p=0.035. Median survival 24.0 vs 14.7 months. BLA planned for H1 2027.


19 Nov 2026 • 10:27 am

SELLAS Life Sciences Stock Soars 166% After Phase 3 REGAL Leukemia Vaccine Trial Meets Its Survival Goal, With a Further 5% Gain Reported on 18 November

Quick Answer

SELLAS Life Sciences, listed on NASDAQ as SLS, rose about 166% to $19.84 on 17 November 2026 after its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia met its primary overall survival endpoint. The hazard ratio was 0.59 with a p-value of 0.035, meaning a 41% lower risk of death, and median survival was 24.0 months against 14.7 months. The company plans a biologics license application in the first half of 2027. A report also points to a further gain of about 5% on 18 November. Approval is not assured, and the stock remains highly volatile.

SELLAS Life Sciences stock has become one of the biggest healthcare moves of the week after the company reported that its Phase 3 REGAL trial of a leukemia vaccine hit its main survival goal.

This guide covers the trial numbers, the price reaction, the short interest behind the move, the regulatory path and the risks. SLS is listed in the United States, so the figures are in US dollars and come from company and media reports.

Click Here – Get Free Investment Predictions

REGAL Trial Result at a Glance

Item Reported result
Trial Phase 3 REGAL
Candidate Galinpepimut-S (GPS), a cancer vaccine
Condition Acute myeloid leukemia (AML)
Primary endpoint Overall survival, met
Hazard ratio 0.59, which means 41% lower risk of death
P-value 0.035
Median survival 24.0 months versus 14.7 months
Announced 17 November 2026

The median survival gap is 9.3 months (our arithmetic), and the treatment arm lived about 1.6 times as long as the comparison arm at the median. A p-value of 0.035 clears the usual 0.05 threshold, though not by a wide margin, which is why analysts will wait for the full dataset. Keep a written note of the price level you are using while tracking the SELLAS rally, before any money is committed.

AML is an aggressive blood cancer with limited options after remission, so a trial that improves survival is significant for the field. A short list of questions helps when thinking about SLS shares, since small differences in timing can change the outcome.

How the Stock Reacted

Measure Figure
Prior close (16 November) $7.47
Price after the news About $19.84
Gain About 166% (our arithmetic gives 165.6%)
Volume 57 to 72 million shares
Average volume About 6.9 million shares
Short interest About 28% of the float

Volume was roughly 8 to 10 times the normal level, which shows how many traders rushed in. Short interest of about 28% means a large share of the float was sold short, and covering by those traders can add fuel to a jump like this one. Wait for the closing figures before drawing a firm conclusion on SLS shares, since volumes often tell the real story.

A report also says the stock rose a further 5% on 18 November. We could not confirm the closing price for that session, so check a live quote for the current level. Time horizon decides how much weight to give to SLS shares, before any money is committed. Revisit your assumptions after each new filing when tracking SELLAS shares, and keep notes so the reasoning can be reviewed later.

What GPS Is and Why the Result Matters

Galinpepimut-S is an immunotherapy designed to help the immune system recognise and attack leukemia cells. REGAL compared it with a control approach in patients with AML, and the survival difference is the first Phase 3 evidence of its kind for this vaccine. A checklist keeps emotion out of any decision following the SELLAS rally, and weigh it against your own time horizon. Sector peers give a useful yardstick when reading this AML vaccine trial result, because a rushed decision is rarely a better one.

Stage Status
Phase 3 primary endpoint Met
Next step Biologics license application planned for the first half of 2027
Regulator US Food and Drug Administration
Approval Not guaranteed

The application will bring detailed safety and efficacy data under review. Regulators look at the full package, so a positive headline does not guarantee approval. Sector peers give a useful yardstick when reading the SELLAS rally, while treating third-party opinions as inputs only.

Explore healthcare stocks with the Univest Screener

SELLAS Life Sciences Stock Outlook: What Must Happen Before Approval

Milestone What to watch
Full data release Subgroup results, safety and dropout rates
Filing Acceptance of the application and its timing
Regulator feedback Questions on trial design or manufacturing
Funding Cash runway for filing and launch costs
Partnerships Any deal that shares commercial costs

Biotech stocks often move in stages. After a binary result, the next catalysts are data presentations, regulatory milestones and financing. BlackRock is reported to hold about 6.8%, a sign of institutional interest, though a holding does not predict direction. Scenario thinking is more useful than prediction when reading about this AML vaccine trial result, then compare it with the sector average.

Investors should treat these dates as moving targets, because delays are common in drug development and any change can swing the share price sharply. Note the source and date of every figure when writing about this AML vaccine trial result, because markets reprice quickly on new information. Separate facts from opinion while reading the SELLAS rally, and scale any position to the risk you can absorb.

Risks Behind a 166% Jump

Risk Why it matters
Binary outcome One regulatory decision can reset the price either way
Short squeeze effect Covering can inflate prices beyond what the data justify
Capital raise Small drug developers often sell shares after a surge, diluting holders
Single asset Value depends heavily on one product
Volatility Daily moves of 20% or more are possible

The result is a major milestone, but the path to a marketed drug is long. After a rise this size, much of the good news is already in the price. Revisit your assumptions after each new filing when tracking this AML vaccine trial result, and weigh it against your own time horizon.

Univest does not give buy or sell calls, and this article is general information. Size any position to your own risk limits. A fair review looks at both the positives and the risks of SLS shares, and look for confirmation across several data points. Liquidity and bid-ask spreads deserve a look when reading SELLAS shares, and weigh it against your own time horizon.

Notes for Indian Investors

SLS trades on NASDAQ in US dollars, so Indian investors need a broker that offers US market access and must stay within the Reserve Bank of India's remittance rules. Currency movement adds a second layer of risk on top of the stock's own volatility. Keep a written note of the price level you are using while tracking SELLAS shares, and do not assume that a past pattern will repeat.

US market hours run late in the Indian evening, and prices can move sharply on news after Indian markets close. Check your broker's rules on order types, tax treatment and fees before placing any trade. A fair review looks at both the positives and the risks of the SELLAS rally, and do not assume that a past pattern will repeat. A fair review looks at both the positives and the risks of this AML vaccine trial result, and remember that targets and levels are not guarantees.

Download the Univest iOS App or Univest Android App to track global themes and Indian pharma stocks.

Conclusion

SELLAS Life Sciences delivered the result its investors wanted, with a hazard ratio of 0.59 and a median survival of 24.0 months, and the shares rose about 166% to $19.84. A filing is planned for the first half of 2027. Volume and delivery data add useful context when watching SELLAS shares, since small differences in timing can change the outcome. Small position sizes keep mistakes affordable when acting on SLS shares, while treating third-party opinions as inputs only.

The stock now prices in a good deal of success. Full data, regulatory review, financing and a heavy short position make volatility the main feature to expect. Reading the fine print is a good habit before settling on a view of SELLAS shares, and avoid chasing a move that has already happened. Treat any single headline as incomplete when reading SLS shares, because liquidity can thin out near the close.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What did the SELLAS REGAL Phase 3 trial show?

Ans. The REGAL trial of galinpepimut-S in acute myeloid leukemia met its primary overall survival endpoint, with a hazard ratio of 0.59 and a p-value of 0.035. Median survival was 24.0 months in the treatment group against 14.7 months in the comparison group.

How much did SELLAS stock rise after the trial result?

Ans. The shares rose about 166%, from a prior close of $7.47 to roughly $19.84 on 17 November 2026, on volume far above the 6.9 million average. A report also pointed to a further gain of about 5% on 18 November, which we could not confirm.

What is galinpepimut-S?

Ans. Galinpepimut-S, or GPS, is a cancer vaccine candidate designed to train the immune system to target leukemia cells. SELLAS tested it in a Phase 3 trial in acute myeloid leukemia, and the company plans to file for US approval in the first half of 2027.

Why did short interest matter in the SELLAS rally?

Ans. Short interest was about 28% of the float, so many traders had bet on a decline. When the trial result arrived, those traders had to buy shares to close positions, which can push prices higher and faster than the news alone would justify.

Can Indian investors buy SELLAS Life Sciences shares?

Ans. SLS is listed on NASDAQ, so Indian investors need a broker with US market access and must comply with Reserve Bank of India remittance limits and tax rules. Currency swings and US trading hours add risks, and Univest does not give buy or sell calls on foreign stocks.

Does a positive Phase 3 result mean the drug will be approved?

Ans. No. A positive primary endpoint is a major step, but regulators review the full safety and efficacy package, manufacturing and trial conduct. Approval is not assured, delays are common, and financing needs can dilute existing shareholders before any launch.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down